Bowel cancer treatment has been boosted by recent breakthroughs that offer hope of gene-related treatments for the condition.
Genetic biomarkers linked to bowel cancer have been identified by a series of studies that are detailed in the journal Therapeutic Advances in Medical Oncology.
Establishing the role of genetic material has increased the chance of targeted and personalised medication being administered, which is a more effective cancer treatment.
One such example is the recently published paper by Dr Axel Grothey, 'Medical treatment of advanced colorectal cancer', in which he outlines the various new cancer treatments that have emerged this year.
Mayo Clinic oncologist Dr Axel Grothey commented: "It cannot be overemphasised that these significant improvements in outcome of patients with CRC are closely linked to the number of active drugs available to treat this disease.
"Although biomarkers will provide some guidance on which agents are potentially useful in a given setting, in particular with regard to the use of EGFR antibodies, the importance of individualising therapy based on clinical parameters cannot be overemphasised."
A recent study published by the Harvard Medical School in Boston in Boston has revealed that taking aspirin could help protect against bowel cancer and may also reduce mortality rates.